All GLG News Analyses Filed Under: Oncology

benefit of Iressa

April 27, 2009

Analysis by: GLG Expert Contributor

Analysis of:IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com

I have a patient with non small cell carcinoma of the lung who has had a great response for over seven years on this medication. She was a perfect fit- female, non smoker. After seven years she is NED. She was close to being referred to hospice seven years ago. She is receiving the med at present free of charge from the company. I hope that ultimately this agent will again be available in the US. Stephen Schreibman, MD

More to do...

April 13, 2009

Analysis by: GLG Expert Contributor

Analysis of:Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN® and Radiation Combination Clinical Trial | www.pipelinereview.com

+ Single arm + Efficacy hard to determine + Large scale/arm multi-site trial needed

Denosumab May Help to Salvage Bone Health in Metastatic Disease

April 13, 2009

Analysis by: GLG Expert Contributor

Analysis of:Randomized Phase II Trial Of Denosumab In Patients With Bone Metastases From Prostate Cancer, Or Other Neoplasms After Intravenous Bisphosphonates | www.medicalnewstoday.com

Metastatic spread to the bone is a common and problematic complication for many patients with advanced cancer.  Current treatment with bisphosphonates only modestly controls skeletal spread. This study suggests that the monoclonal antibody Denosumab has biologic and clinical activity to help patients who are at risk for further bone metastases despite bisphosphonate therapy.

Is It Time To Replace The 'Pap' Test With HPV Viral Testing?

April 5, 2009

Analysis by: GLG Expert Contributor

Analysis of:Viral screening test effective against cervical cancer | www.hindu.com

- Provides evidence by a large scale trial to show HPV testing is feasible - Provides evidence that HPV testing is possible using scant resources in   developing countries where cervical cancer is most common and   deadly - Provides evidence that HPV testing has much better negative and    positive predictive values in predicting cervical cancer and its    precursors -  Lends credence to the suggestion that it may be time to replace the     traditional 'Pap' by the HPV test

Enrollment in Poniard's Phase III Study of Picoplatin is Complete

March 29, 2009

Analysis by: GLG Expert Contributor

Analysis of:PipelineReview.com - Biotech News | www.pipelinereview.com

Small Cell lung cancer is tough to treat, especially when it recurs after prior therapy, and treatment options are limited.  Picoplatin is a new-generation platinum chemotherapy, and is being studied by Poniard Pharmaceuticals (PARD) in a randomized, 400-patient, phase III study.

THE IMPORTANCE OF PROPER DOSING AND ROUTE OF ADMINISTRATION

March 26, 2009

Analysis by: GLG Expert Contributor

Analysis of:Cancer drug 'fuels tumour growth' | news.bbc.co.uk

This is an excellent paper to demonstrate the importance of a good phase I trial with detailed pharmacokinetics, dosing and continuous vs. bolus administration of each anti cancer drugs. The finding regarding low dosing of this drug as causative of enhancement of cancer should not effect the potential use of this drug, especially in combination with anti VEGF-R2 drugs currently in use.

RNA Inhibitor Development: A Matter of Pipeline Strategy and Technology Risk

March 26, 2009

Analysis by: GLG Expert Contributor

Analysis of:Another LNA-based RNA Inhibitor Enters Clinical Trials | www.pipelinereview.com

Swedish company Santaris has developed several RNA antagonists to key protein targets in the biology of cancers. Two of those are in collaboration with ENZON for solid tumors. One targets hypoxia-inducible factor 1 alpha (HIF1a), the second targets survivin, a protein shown to protect rapidly growing cells (cancer and fetal) from apoptosis and is also implicated in the cell cycle. Technology risk is being managed with advance of multiple targets into early trials. The challenge will be in making sound choices before Phase III.

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

Another good result for Roche.

March 23, 2009

Analysis of:UPDATE 1-Roche's Herceptin prolongs stomach cancer survival | www.reuters.com

The results from ToGA, a large international phase III trial, showed the benefit of herceptin plus chemotherapy vs chemotherapy alone as the first therapy for patients with advanced unresectable gastric cancer.  

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

A Novel Option for Management of Malignant Ascites.

March 23, 2009

Analysis of:COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE: SUMMARY OF POSITIVE OPINION FOR REMOVAB | www.emea.europa.eu

Catumaxomab is a trifunctional monoclonal antibody with 2 antigen-recognition sites: one for human EpCAM, a cell surface antigen expressed by a variety of epithelial tumor cells, and one for human CD3, a T-cell surface antigen. In addition, another region of the antibody binds to receptors that are expressed on other cells of the immune system.

Cautious optimism appropriate for a cancer with a historically dismal outlook.

March 23, 2009

Analysis by: GLG Expert Contributor

Analysis of:UPDATE 1-Roche's Herceptin prolongs stomach cancer survival | www.reuters.com

Many adenocarcinomas and sqamous cell cancers express HER2 . However, HER2 based therapy is only approved therapy in early and late stage breast cancer. 25% of gastric cancers express HER2. The Toga trial was conducted practically everywhere except the US; indeed there are geographic differences in gastric cancer in regards to risks, location, age of diagnosis, stage at presention, etc.. which are notable. However, the trial appears well powered between arms. The ToGA trial used a somewhat outdated regimen as control (5FU +CDDDP) however for study purposes that was appropriate. Other regimens will be compared to the H+chemo arm across studies (TPF, regimens investigated in REAL, etc..). I would assume minimal toxicity was added with H (aside from cardiac). Although we should all be optimistic (gastric cancer has a 5 yr median survival of 10-15%; incidence of proximal gastric and GE cancer is increasing more than any other cancer) results will need to be scrutinized when available.

Previous Page : 12345678910Next31 to 40 of 900